🔗 Share this article Individuals Coming Off Anti-Obesity Medications Gain Back Pounds Far More Rapidly Than Those on Conventional Diets Weight management often requires long-term strategies. Fresh analysis indicates that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on shed pounds far faster than those who end conventional lifestyle programs. Research printed in a major health publication demonstrates that while overweight people often shed a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping. "Individuals buying these medications need to be aware of the risk of quick weight regain when the medication ends," stated lead investigator Dr. Susan Jebb. This pace of recovery implies a return to pre-treatment weight within about 18 months. Weighing Therapies The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting. Researchers point out that individuals who lose weight through diet and exercise generally see a slower creep back—around 0.1 kg a month—after stopping. Explaining the Quick Regain Doctors suggest the mode of action of the drugs accounts for the accelerated rebound. The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger. "Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating much more probable." An Ongoing Issue? Medical guidelines advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications. Professionals argue that, considering the significant potential of weight regain, the treatment might need to be long-term. This view is echoed by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension. User Testimonies Users who have come off the medication explain a sudden return of hunger. "It felt as if a trigger activating and I was suddenly extremely hungry," recalled an individual. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit modifications during therapy. Significant Use Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among females than men. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private healthcare rather than the NHS. In conclusion, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and maintained weight loss likely depends on ongoing lifestyle management.
Weight management often requires long-term strategies. Fresh analysis indicates that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on shed pounds far faster than those who end conventional lifestyle programs. Research printed in a major health publication demonstrates that while overweight people often shed a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping. "Individuals buying these medications need to be aware of the risk of quick weight regain when the medication ends," stated lead investigator Dr. Susan Jebb. This pace of recovery implies a return to pre-treatment weight within about 18 months. Weighing Therapies The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting. Researchers point out that individuals who lose weight through diet and exercise generally see a slower creep back—around 0.1 kg a month—after stopping. Explaining the Quick Regain Doctors suggest the mode of action of the drugs accounts for the accelerated rebound. The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger. "Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating much more probable." An Ongoing Issue? Medical guidelines advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications. Professionals argue that, considering the significant potential of weight regain, the treatment might need to be long-term. This view is echoed by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension. User Testimonies Users who have come off the medication explain a sudden return of hunger. "It felt as if a trigger activating and I was suddenly extremely hungry," recalled an individual. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit modifications during therapy. Significant Use Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among females than men. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private healthcare rather than the NHS. In conclusion, researchers caution that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and maintained weight loss likely depends on ongoing lifestyle management.